Skip to content
26 Jan 2021

Topic: Viral hepatitis

Meeting Type: EASL meetings


Hepatitis C virus (HCV) infection is a major cause of chronic liver disease, with approximately 71 million chronically infected individuals worldwide. Clinical care for patients with HCV-related liver disease has advanced considerably thanks to an enhanced understanding of the pathophysiology of the disease, as well as developments in diagnostic procedures and improvements in therapy and prevention. These therapies make it possible to eliminate hepatitis C as a major public health threat, as per the World Health Organization target, although the timeline and feasibility vary from region to region.

The EASL Recommendations on Treatment of Hepatitis C Webinar is intended to assist physicians and other healthcare providers, in the clinical decision-making process, by describing the current optimal management of patients with acute and chronic HCV infections.

Access the 2020 EASL Recommendations on Treatment of Hepatitis C slide deck.

Why attend

Live Webinar Faculty

  • Thomas Berg, University of Leipzig, Leipzig, Germany
  • Jean-Michel Pawlotsky, University of Paris-Est, Paris, France
  • Marina Berenguer, La Fe University and Polytechnic Hospital, Valencia, Spain
  • Geoffrey Dusheiko, University College London School of Medicine, London, United-Kingdom

Panel Members

  • Francesco Negro, University Hospital of Geneva, Geneva, Switzerland
  • Fiona Marra, University of Liverpool, Liverpool, United-Kingdom
  • Olav Dalgard, Akershus University Hospital, Lørenskog, Norway
  • Heiner Wedemeyer, The Hannover Medical School, Hannover, Germany
  • Alessio Aghemo, Humanitas Research Hospital, Milan, Italy
  • Massimo Puoti, The Ospedale Maggiore Policlinico of Milan, Milan, Italy


Time Title
18:00-18:15 Presentation of the new EASL Recommendations

Jean-Michel Pawlotsky

18:15-18:20 Extra-hepatic manifestations

Francesco Negro

18:20-18:25 Children and pregnant women

Fiona Marra

18:25-18:30 PWID and prisoners

Olav Dalgard

18:30-18:35 Organ (including liver) transplant setting

Marina Berenguer

18:35-18:40 Hepatocellular carcinoma

Geoffrey Dusheiko

18:40-18:45 Recently acquired hepatitis C

Heiner Wedemeyer

18:45-18:50 Treatment failures and retreatment

Alessio Aghemo

18:50-18:55 Reinfections

Massimo Puoti

18:55-19:30 Q&A session

Marina Berenguer

Geoffrey Dusheiko

Jean-Michel Pawlotsky

Thomas Berg

Target audience

  • Hepatologists
  • Health care professionals
  • General HCV-treatment practitioners

Learning objectives

  • Understand how to treat HCV infection in 2021 and beyond
  • Learn how to use simplified HCV therapy to improve access to care
  • Learn about new recommendations on special groups and comorbidities
  • Understand how to handle patients with DAA treatment failures
  • Apprehend how to implement simple treatment rules to achieve HCV elimination goals
Back To Top